This is consistent with other clinical trials and database analyses of daptomycin at doses ≥ 6 mg/kg in the treatment of osteomyelitis, in which CPK elevations have been reported in 2.5–8.3 % of patients [8, 22]. The gene discussed is PIK3C2A; the disease is osteomyelitis.